Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAD603 dose-finding study in adults with severe to very severe alopecia areata
2025-523342-27-00Phase 2Authorised
- Sponsor
- Almirall
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing LAD603 with Placebo (2 arms). Primary endpoint: Percent change from baseline in SALT score at Week 36. Planned start Apr 2026; status: authorised.
02
Drugs
LAD603
03
Conditions
alopecia areata
Beyond the preview
Go deeper on 2025-523342-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523342-27-00.